Patients with NSCLC receiving neoadjuvant chemotherapy followed by surgery were found to have higher infiltrating levels of epithelial CD3 + CD4 + T lymphocytes and CD68 + epithelial and stromal tumor-associated macrophages than patients with prior surgery [5]. This evidence concerns the gene CD4 and neoplasm.